Becton

BD to acquire Bard for $24B

Monday, May 1, 2017

BD (Becton, Dickinson and Company), a global medical technology company, and C. R. Bard, a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced a definitive agreement under which BD will acquire Bard for $317 per Bard common share in cash and stock, for a total consideration of $24 billion. The agreement has been unanimously approved by the Boards of Directors of both companies.

[Read More]